Boosting dendritic cell nanovaccines

Yahya Mohammadzadeh^{1

2

3}, Michele De Palma^{4

5

6}

Affiliations

¹ Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
² Agora Cancer Research Center, Lausanne, Switzerland.
³ Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.
⁴ Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. michele.depalma@epfl.ch.
⁵ Agora Cancer Research Center, Lausanne, Switzerland. michele.depalma@epfl.ch.
⁶ Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. michele.depalma@epfl.ch.

Comment

Yahya Mohammadzadeh et al. Nat Nanotechnol. 2022 May.

. 2022 May;17(5):442-444.

doi: 10.1038/s41565-022-01089-1.

Yahya Mohammadzadeh^{1

2

3}, Michele De Palma^{4

5

6}

¹ Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland.
² Agora Cancer Research Center, Lausanne, Switzerland.
³ Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland.
⁴ Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, Swiss Federal Institute of Technology in Lausanne (EPFL), Lausanne, Switzerland. michele.depalma@epfl.ch.
⁵ Agora Cancer Research Center, Lausanne, Switzerland. michele.depalma@epfl.ch.
⁶ Swiss Cancer Center Léman (SCCL), Lausanne, Switzerland. michele.depalma@epfl.ch.

No abstract available

Comment on

A nanovaccine for antigen self-presentation and immunosuppression reversal as a personalized cancer immunotherapy strategy.
Liu C, Liu X, Xiang X, Pang X, Chen S, Zhang Y, Ren E, Zhang L, Liu X, Lv P, Wang X, Luo W, Xia N, Chen X, Liu G. Liu C, et al. Nat Nanotechnol. 2022 May;17(5):531-540. doi: 10.1038/s41565-022-01098-0. Epub 2022 Apr 11. Nat Nanotechnol. 2022. PMID: 35410368

1. Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 1–10 (2019). - DOI
1. Pitt, J. M. et al. Dendritic cell-derived exosomes for cancer therapy. J. Clin. Invest. 126, 1224–1232 (2016). - DOI
1. Liu et al. Antigen Self-Presenting Nanovaccine with Immunosuppression Reversal (ASPIRE) for Personalized Cancer Immunotherapy. Nat. Nanotechnol. https://doi.org/10.1038/s41565-022-01084-6 (2022). - DOI
1. Squadrito, M. L., Cianciaruso, C., Hansen, S. K. & De Palma, M. EVIR: Chimeric receptors that enhance dendritic cell cross-dressing with tumor antigens. Nat. Methods 15, 183–186 (2018). - DOI
1. Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018). - DOI